Antitumor composition
Patent Information
- Application Number
- JP2024118380
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-03-25
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
【0008】 特定の抗腫瘍剤と、特定の化合物とを組み合わせて用いることにより、単独で用いる場合の抗腫瘍効果よりもさらに高い抗腫瘍効果を得られうる。
Smart Images

Figure 2024156732000024 
Figure 2024156732000025 
Figure 2024156732000026
Abstract
Description
[Technical field]
[0001] The present disclosure relates to an antitumor composition, a method for preventing or treating a tumor, etc. All of the documents described in this specification, including the documents listed below as prior art documents (patent documents and non-patent documents), are incorporated herein by reference in their entirety. [Background technology]
[0002] The number of people who die from malignant tumors (cancer) is on the rise. For this reason, there is a constant demand for superior methods of treating malignant tumors, and these methods are being developed on a daily basis. [Prior art documents] [Patent documents]
[0003] [Patent Document 1] International Publication No. 2012 / 046825 Summary of the Invention [Problem to be solved by the invention]
[0004] In general, when administering an antitumor agent alone in chemotherapy for tumors, especially malignant tumors, there is a limit to the extent to which it can exert a sufficient antitumor effect due to side effects, etc. Therefore, in clinical practice, multiple drug combination therapy is carried out by combining two or more different agents. This combination therapy combines different antitumor agents to 1) reduce the population of non-sensitive cells, The purpose is to reduce side effects or enhance anti-tumor effects, such as 2) preventing or delaying the emergence of drug resistance, and 3) dispersing toxicity by combining drugs with different toxicities.
[0005] However, random combination therapy of different antitumor agents does not necessarily result in enhanced antitumor activity. Moreover, when multiple antitumor agents are used in combination, side effects are often increased along with the antitumor activity. Therefore, there is a demand for a new combination of antitumor agents that can significantly reduce tumor size through synergistic antitumor activity without increasing side effects as much as possible. [Means for solving the problem]
[0006] The inventors have discovered that a combination of a specific antitumor agent and a specific compound can provide an antitumor effect that is stronger than the antitumor effect achieved when either compound is used alone, and have made further improvements.
[0007] The present disclosure includes, for example, the subject matter described in the following sections: Section 1. An antitumor composition comprising the following compound (B) or a salt thereof for use in combination with the following antitumor agent (A). (A) at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, folate antimetabolites, Bcl-2 inhibitors, and tyrosine kinase inhibitors; (B) Formula (1) below: [ka] (In the formula, R 1 represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group which may be substituted with one or more halogen atoms, R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, m represents an integer from 1 to 3, provided that when m represents 2 or 3, R 1 are the same or different) or a salt thereof Section 2. An antitumor composition comprising the following compound (B) or a salt thereof, which is administered to a person who will be administered or has been administered an antitumor agent (A) below. (A) at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, folate antimetabolites, Bcl-2 inhibitors, and tyrosine kinase inhibitors; (B) Formula (1) below: [ka] (In the formula, R 1 represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group which may be substituted with one or more halogen atoms, R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, m represents an integer from 1 to 3, provided that when m represents 2 or 3, R 1 are the same or different) or a salt thereof Section 3. The following antitumor agents (A), and The following compound (B) or a salt thereof: 13. An antitumor composition comprising: (A) at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, folate antimetabolites, Bcl-2 inhibitors, and tyrosine kinase inhibitors; (B) Formula (1) below: [ka] (In the formula, R 1 represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group which may be substituted with one or more halogen atoms, R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, m represents an integer from 1 to 3, provided that when m represents 2 or 3, R 1 are the same or different) or a salt thereof Section 4. The compound (B) or a salt thereof is N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide, N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide, N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, 2-fluoro-N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, 2,3,4-trifluoro-N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}benzamide, N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide, N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide, N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, 2-fluoro-N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide], N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide, N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide, N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide, 2-fluoro-N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, 2,3,4-trifluoro-N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}benzamide, 2,3,4-trifluoro-N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}benzamide, N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, 2-Fluoro-N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, and 2,3,4-Trifluoro-N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}benzamide At least one compound selected from the group consisting of or a salt thereof, The composition according to any one of items 1 to 3. Section 5. The following antitumor agents (A), and An antitumor composition comprising the following compound (B) or a salt thereof: A kit comprising: (A) at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, folate antimetabolites, Bcl-2 inhibitors, and tyrosine kinase inhibitors; (B) Formula (1) below: [ka] (In the formula, R 1represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group which may be substituted with one or more halogen atoms, R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, m represents an integer from 1 to 3, provided that when m represents 2 or 3, R 1 are the same or different) or a salt thereof Section 6. A method for preventing or treating a tumor, comprising administering to a subject an antitumor agent represented by the following formula (A) and a compound represented by the following formula (B) or a salt thereof. (A) at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, folate antimetabolites, Bcl-2 inhibitors, and tyrosine kinase inhibitors; (B) Formula (1) below: [ka] (In the formula, R 1 represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group which may be substituted with one or more halogen atoms, R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, m represents an integer from 1 to 3, provided that when m represents 2 or 3, R 1 are the same or different) or a salt thereof Section 7. A compound represented by the following (B) or a salt thereof for use in combination with an antitumor agent represented by the following (A) in the prevention or treatment of a tumor. (A) at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, folate antimetabolites, Bcl-2 inhibitors, and tyrosine kinase inhibitors; (B) Formula (1) below: [ka] (In the formula, R 1 represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group which may be substituted with one or more halogen atoms, R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, m represents an integer from 1 to 3, provided that when m represents 2 or 3, R 1 are the same or different) or a salt thereof Section 8. (A) an antitumor agent, A compound having two or more alkyl groups capable of covalently bonding with DNA bases; an anti-CD20 antibody or a fragment thereof that recognizes the CD20 antigen, an aptamer that recognizes the CD20 antigen, or a conjugated molecule comprising either of them (preferably an antibody-drug conjugate (ADC)); DNA methyltransferase inhibitors, Pyrimidine antimetabolites, purine antimetabolites, and folate antimetabolites, Bcl-2 inhibitors, and Tyrosine Kinase Inhibitors At least one selected from the group consisting of The composition according to any one of items 1 to 4, the kit according to item 5, the prophylactic or therapeutic method according to item 6, or the compound or a salt thereof according to item 7. Section 9. (A) an antitumor agent, Nitrogen mustards (e.g., mechlorethamine hydrochloride, cyclophosphamide, ifosfamide, melphalan, chlorambucil, bendamustine), aziridines and epoxides (e.g., thiotepa, mitomycin C, and dianhydrogalactitol), alkylsulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, and ranimustine), hydrazine and triazene derivatives (e.g., procarbazine, dacarbazine, and temozolomide), Rituximab, ibritumomab, and antibodies whose comparability with rituximab or ibritumomab has been confirmed (biosimilars of rituximab or ibritumomab), Ibritumomab tiuxetan, Decitabine, Azacitidine, and Zebularine cytarabine, 5-FU (5-fluorouracil), azathioprine, mercaptopurine, and methotrexate, Venetoclax, and Lapatinib, gefitinib, imatinib, ponatinib, erlotinib, ibrutinib, axitinib, lenvatinib, afatinib, and gilteritinib At least one selected from the group consisting of The composition according to any one of items 1 to 4, the kit according to item 5, the prophylactic or therapeutic method according to item 6, or the compound or a salt thereof according to item 7. Effect of the Invention
[0008] By using a specific antitumor agent in combination with a specific compound, it is possible to obtain an antitumor effect that is greater than the antitumor effect obtained when either is used alone. [Brief description of the drawings]
[0009] [Figure 1]This is the result of an isobologram analysis showing the combined effect of N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide hydrochloride (hereinafter also referred to as "Compound A" in the brief description of the drawing) and bendamustine in the human follicular lymphoma cell line DOHH-2. [Diagram 2] 1 shows the results of an isobologram analysis showing the combined effect of compound A and bendamustine on the human breast cancer cell line MDA-MB-231. [Diagram 3] 1 shows the results of an isobologram analysis showing the combined effect of Compound A and decitabine on human acute myeloid leukemia (AML) cell line CMK-86. [Figure 4] 1 shows the results of isobologram analysis showing the combined effect of compound A and busulfan on human acute myeloid leukemia (AML) cell line MV-4-11. [Diagram 5] 1 shows the results of isobologram analysis showing the combined effect of Compound A and lomustine in human chronic myeloid leukemia (CML) cell line K562. [Figure 6] 1 shows the results of an isobologram analysis showing the combined effect of compound A and thiotepa in human lung cancer cell line A549. [Figure 7] 1 shows the results of isobologram analysis showing the combined effect of Compound A and lomustine in human pancreatic cancer cell line BxPC-3. [Figure 8] 1 shows the results of isobologram analysis showing the combined effect of compound A and melphalan on human acute myeloid leukemia (AML) cell line KG-1. [Figure 9] 1 is an isobologram analysis result showing the combined effect of Compound A and lomustine in human diffuse large B-cell lymphoma (DLBCL) cell line U2932. [Figure 10] 1 is an isobologram analysis result showing the combined effect of compound A and melphalan in human diffuse large B-cell lymphoma (DLBCL) cell line U2932. [Figure 11]1 shows the results of isobologram analysis showing the combined effect of compound A and melphalan on human acute myeloid leukemia (AML) cell line MV-4-11. [Figure 12] 1 shows the results of isobologram analysis showing the combined effect of Compound A and lomustine in human gastric cancer cell line MKN45. [Figure 13] 1 shows the results of an isobologram analysis showing the combined effect of Compound A and decitabine on human acute myeloid leukemia (AML) cell line MV-4-11. [Figure 14] 1 is an isobologram analysis result showing the combined effect of Compound A and decitabine on human acute myeloid leukemia (AML) cell line OCI-AML2. [Figure 15] 1 shows the results of isobologram analysis showing the combined effect of compound A and cytarabine on human acute myeloid leukemia (AML) cell line MV-4-11. [Figure 16] 1 shows the results of an isobologram analysis showing the combined effect of compound A and bendamustine in human breast cancer cell line BT-474. [Figure 17] 1 shows the results of isobologram analysis showing the combined effect of Compound A and melphalan in human multiple myeloma cell line RPMI 8226. [Figure 18] 1 is an isobologram analysis result showing the combined effect of compound A and venetoclax on human acute myeloid leukemia (AML) cell line KG-1. [Figure 19] 1 shows the results of isobologram analysis showing the combined effect of Compound A and ranimustine in human chronic myeloid leukemia (CML) cell line K562. [Figure 20] 1 is an isobologram analysis result showing the combined effect of Compound A and thiotepa in human ovarian cancer cell line SK-OV-3. [Figure 21] 1 shows the results of an isobologram analysis showing the combined effect of Compound A and ibrutinib on human acute myeloid leukemia (AML) cell line MV-4-11. [Figure 22]1 shows the results of isobologram analysis showing the combined effect of Compound A and decitabine on human myelodysplastic syndrome cell line SKM-1. [Diagram 23] 1 shows the results of isobologram analysis showing the combined effect of compound A and erlotinib in human lung cancer cell line A549. [Figure 24] 1 shows the results of isobologram analysis showing the combined effect of compound A and gefitinib in human lung cancer cell line A549. [Diagram 25] 1 shows the results of an isobologram analysis showing the combined effect of Compound A and gefitinib in human lung cancer cell line HCC 827. [Figure 26] 1 shows the results of isobologram analysis showing the combined effect of Compound A and imatinib on human chronic myeloid leukemia (CML) cell line K562. [Figure 27] 1 shows the results of an isobologram analysis showing the combined effect of compound A and axitinib in human renal cancer cell line ACHN. [Figure 28] 1 is an isobologram analysis result showing the combined effect of Compound A and lapatinib in human breast cancer cell line MDA-MB-453. [Figure 29] 1 shows the results of isobologram analysis showing the combined effect of compound A and lenvatinib in human hepatic cancer cell line Hep G2. [Diagram 30] 1 shows the results of an isobologram analysis showing the combined effect of Compound A and lapatinib in human breast cancer cell line SK-BR-3. [Diagram 31] 1 shows the results of an isobologram analysis showing the combined effect of compound A and afatinib in human lung cancer cell line A549. [Diagram 32] 1 is an isobologram analysis result showing the combined effect of compound A and gilteritinib on human acute myeloid leukemia (AML) cell line MV-4-11. [Diagram 33] 1 shows the results of isobologram analysis showing the combined effect of compound A and 5-FU in human head and neck (pharyngeal) cancer cell line FaDu. [Diagram 34]1 is an isobologram analysis result showing the combined effect of Compound A and vincristine on the human diffuse large B-cell lymphoma cell line OCI-Ly18. [Diagram 35] 1 shows the results of an isobologram analysis showing the combined effect of Compound A and docetaxel in human breast cancer cell line BT-474. [Diagram 36] 1 shows the results of the combined effect of Compound A and cyclophosphamide in human diffuse large B-cell lymphoma cell line OCI-Ly7. [Figure 37] 1 shows the results of the combined effect of Compound A and cyclophosphamide in human diffuse large B-cell lymphoma cell line OCI-Ly7. [Figure 38] 1 shows the results of the combined effect of Compound A and cyclophosphamide in human diffuse large B-cell lymphoma cell line OCI-Ly7. [Figure 39] 1 shows the results of the combined effect of Compound A and lapatinib on the human breast cancer cell line MDA-MB-453. [Diagram 40] 1 shows the results of the combined effect of Compound A and lapatinib on the human breast cancer cell line MDA-MB-453. [Diagram 41] 1 shows the results of the combined effect of Compound A and bendamustine in human diffuse large B-cell lymphoma cell line OCI-Ly7. [Diagram 42] 1 shows the results of the combined effect of Compound A and Rituximab in the human diffuse large B-cell lymphoma cell line OCI-Ly7. [Diagram 43] 1 shows the results of the combined effect of Compound A and decitabine on human acute myeloid leukemia (AML) cell line KG-1. [Diagram 44] 1 shows the results of the combined effect of Compound A and cytarabine on human acute myeloid leukemia (AML) cell line KG-1. [Diagram 45] 1 shows the results of a triple combination effect of compound A, bendamustine, and rituximab in human diffuse large B-cell lymphoma cell line OCI-Ly7. [Diagram 46]The results show the effect of a triple combination of Compound A, decitabine, and venetoclax in the human acute myeloid leukemia (AML) cell line KG-1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] Each embodiment included in the present disclosure will be described in more detail below. The present disclosure preferably includes, but is not limited to, an antitumor composition, a method for preventing or treating a tumor, and a kit for antitumor. The present disclosure includes all that is disclosed in the present specification and that can be recognized by a person skilled in the art.
[0011] The antitumor composition encompassed by the present disclosure contains the following compound (B) or a salt thereof: Hereinafter, an antitumor composition containing the compound (B) or a salt thereof may be referred to as the "antitumor composition of the present disclosure." (B) Formula (1) below: [ka] (In the formula, R 1 represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group which may be substituted with one or more halogen atoms, R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, m represents an integer from 1 to 3, provided that when m represents 2 or 3, R 1 are the same or different) A compound represented by the formula:
[0012] Specific examples of the individual groups shown in formula (1) are as follows.
[0013] Examples of lower alkoxy groups include straight-chain or branched alkoxy groups having 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy groups.
[0014] Examples of lower alkyl groups include straight-chain or branched alkyl groups having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, 2,2-dimethylpropyl, 1-ethylpropyl, butyl, isobutyl, tert-butyl, isopentyl, pentyl, and hexyl groups.
[0015] Examples of lower alkyl groups optionally substituted with one or more halogen atoms include, in addition to the lower alkyl groups described above, straight-chain or branched alkyl groups having 1 to 6 carbon atoms optionally substituted with 1 to 3 halogen atoms, such as trifluoromethyl, trichloromethyl, chloromethyl, bromomethyl, fluoromethyl, iodomethyl, difluoromethyl, dibromomethyl, dichloromethyl, 2-chloroethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, 3-chloropropyl, 2,3-dichloropropyl, 4,4,4-trichlorobutyl, 4-fluorobutyl, 5-chloropentyl, 3-chloro-2-methylpropyl, 5-bromohexyl, and 5,6-dibromohexyl groups.
[0016] Examples of the halogen atom include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
[0017] Examples of aryl groups include C6 to C 10 Aromatic groups include, for example, phenyl, 1-naphthyl, 2-naphthyl, o-tolyl, m-tolyl, and p-tolyl groups.
[0018] Examples of aryloxy groups include C6 to C 10 Aryloxy groups include, for example, phenoxy, 1-naphthyloxy, and 2-naphthyloxy groups.
[0019] A preferred example is R 1represents an aryl group, an aryloxy group, or a lower alkyl group optionally substituted by one or more halogen atoms; R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group; m represents the integer 1; The compound is represented by formula (1) or a salt thereof.
[0020] Another preferred example is R 1 represents a halogen atom, R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group; m represents an integer from 1 to 3; However, when m represents 2 or 3, R 1 are the same or different, The compound is represented by formula (1) or a salt thereof.
[0021] Yet another preferred example is R 1 represents halogen or a lower alkyl group optionally substituted with one or more halogen atoms; R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group; m represents an integer 2; However, R 1 are the same or different, The compound is represented by formula (1) or a salt thereof.
[0022] More specific preferred examples of the compound represented by formula (1) include: N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide, N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide, N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, 2-fluoro-N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, 2,3,4-trifluoro-N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}benzamide, N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide, N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide, N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, 2-fluoro-N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide, N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide, N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide, N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide, 2-fluoro-N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, 2,3,4-trifluoro-N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}benzamide, 2,3,4-trifluoro-N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}benzamide, N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, 2-Fluoro-N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, or 2,3,4-Trifluoro-N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}benzamide The salts of these compounds can also be preferably used.
[0023] Examples of salts of the compound represented by formula (1) include inorganic acid salts such as sulfates, nitrates, hydrochlorides, phosphates, and hydrobromides; sulfonates such as acetates, p-toluenesulfonates, methanesulfonates, and ethanesulfonates; and organic acid salts such as oxalates, maleates, fumarates, malates, tartrates, citrates, succinates, and benzoates.
[0024] The compound represented by formula (1) or a salt thereof can be prepared by a known method or a method that can be easily derived from a known method, for example, by the method described in Patent Document 1 (WO 2012 / 046825).
[0025] The antitumor composition of the present disclosure is used in combination with the following antitumor agent (A). (A) at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, folate antimetabolites, Bcl-2 inhibitors, and tyrosine kinase inhibitors.
[0026] Alkylating agents are a type of cytotoxic anticancer drug (anticancer drug). They form covalent bonds with DNA bases. It has multiple alkyl groups that can bind to DNA and prevents DNA replication by linking two DNA strands together (interstrand crosslinking). DNA bases, especially guanine, are nucleophilic, and generally DNA bases and alkyl groups are covalently bonded by nucleophilic substitution reactions. As alkylating agents, those having two or more alkyl groups are preferred, and more specific examples thereof include nitrogen mustards (e.g., mechlorethamine hydrochloride, cyclophosphamide, ifosfamide, melphalan, chlorambucil, bendamustine), aziridines and epoxides (e.g., thiotepa, mitomycin C, and dianhydrogalactitol), alkylsulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, and ranimustine), hydrazine and triazene derivatives (e.g., procarbazine, dacarbazine, and temozolomide), etc.
[0027] The CD20 recognition molecule here is a molecule that recognizes the CD20 antigen (Bp35) and exhibits an antitumor effect. Examples include an anti-CD20 antibody or a fragment thereof that recognizes the CD20 antigen, an aptamer that recognizes the CD20 antigen, or a composite molecule comprising these. The antibody may be either a polyclonal antibody or a monoclonal antibody, with monoclonal antibodies being preferred. In addition, the antibody is preferably a chimeric antibody (a chimera between a rodent (e.g., mouse, rat, Chinese hamster, etc.) and a human), a humanized antibody, or a fully humanized antibody. Examples of the anti-CD20 antibody include rituximab, ibritumomab, and antibodies whose comparability with rituximab or ibritumomab has been confirmed (rituximab, ibritumomab, etc.). Preferred examples of the conjugated molecule include, more specifically, antibody-drug conjugates (ADCs). Preferred examples of the antibody-drug conjugates are conjugates in which an anticancer drug is bound to an antibody via a linker. Examples of antibody-drug conjugates (ADCs) include, for example, ibritumomab tiuxetan, in which a compound containing a radioisotope (tiuxetan) is bound to an antibody. As shown.
[0028] The DNA methylation inhibitor is preferably a DNA methyltransferase inhibitor, and more specific examples thereof include decitabine, azacytidine, and zebularine.
[0029] Preferred examples of the metabolic antagonists include pyrimidine antimetabolites, purine antimetabolites, and folate antimetabolites. More specifically, examples of the metabolic antagonists include cytarabine, 5-FU (5-fluorouracil), etc., purine antimetabolites include azathioprine, mercaptopurine, etc., and folate antimetabolites include methotrexate, etc.
[0030] Bcl-2 (B cell lymphoma 2) is known as an oncogene that regulates apoptosis by controlling mitochondrial membrane permeability, and an example of a Bcl-2 inhibitor is venetoclax.
[0031] Examples of tyrosine kinase inhibitors include lapatinib, gefitinib, imatinib, ponatinib, erlotinib, ibrutinib, axitinib, lenvatinib, afatinib, gilteritinib, and the like.
[0032] The antitumor composition of the present disclosure can be prepared by combining the compound (B) or a salt thereof with, for example, a pharma- ceutically acceptable carrier, etc. The preparation can be carried out by a known method or a method that can be easily derived from a known method.
[0033] The antitumor composition of the present disclosure is preferably used in the form of a general pharmaceutical preparation. Such pharmaceutical preparations may contain commonly used excipients or additives, such as fillers, extenders, binders, humectants, etc. The formulation can be obtained by using a lubricant, a disintegrant, a surfactant, a lubricant, etc.
[0034] The form of such pharmaceutical preparations can be selected from various forms depending on the purpose of treatment. Typical examples include tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, injections (liquids, suspensions, etc.), etc.
[0035] For forming tablets, for example, lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, and other additives; water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone, and other binders; dry starch, sodium alginate, agar powder, laminaran powder, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan Any of a variety of known carriers may be used, including fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose, and other disintegrating agents; white sugar, stearin, cocoa butter, hydrogenated oils, and other disintegration inhibitors; quaternary ammonium bases, sodium lauryl sulfate, and other absorption enhancers; glycerin, starch, and other humectants; starch, lactose, kaolin, bentonite, colloidal silicic acid, and other adsorbents; purified talc, stearates, boric acid powder, polyethylene glycol, and other lubricants.
[0036] When preparing, for example, sugar-coated tablets, gelatin-coated tablets, enteric-coated tablets, film-coated tablets, bilayer or multilayer tablets, such tablets may be coated with known coating materials as necessary.
[0037] To form pills, a variety of known carriers can be used, including, for example, glucose, lactose, starch, cacao butter, hydrogenated vegetable oils, kaolin, talc, and other additives; powdered gum arabic, powdered tragacanth, gelatin, ethanol, and other binders; laminaran, agar, and other disintegrating agents.
[0038] To form suppositories, various known carriers can be used, including, for example, polyethylene glycol, cacao butter, higher alcohols, esters of higher alcohols, gelatin, semi-synthetic glycerides, and the like.
[0039] To form an injection, the solution, emulsion, or suspension is sterilized and preferably made isotonic with blood. To prepare the solution, emulsion, or suspension, various known and widely used excipients can be used. Examples of such excipients include water, ethanol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, fatty acid ester of polyoxyethylene sorbitan, etc. In this case, the pharmaceutical preparation can contain sodium chloride, glucose, or glycerin in an amount sufficient to prepare an isotonic solution, and can contain common solubilizers, buffers, soothing agents, etc., and further, if necessary, can contain coloring agents, preservatives, flavoring agents, sweetening agents, etc., and / or other medicines.
[0040] Furthermore, the amount of the compound (B) or a salt thereof contained in the antitumor composition of the present disclosure is not particularly limited and may be appropriately selected from a wide range, and may be, for example, about 0.1 to 70% by weight, preferably about 0.1 to 30% by weight in the composition.
[0041] The administration route of the antitumor composition of the present disclosure is not limited. For example, it can be administered by a route suitable for the form of the formulation, the age and sex of the patient, the state of the disease, and other conditions. For example, tablets, pills, liquids, suspensions, emulsions, granules, and capsules are administered orally. Injections are administered intravenously either alone or in combination with a conventional infusion for injection, such as a glucose solution or an amino acid solution. The pharmaceutical composition may be administered intravenously or alone, or, as appropriate, intramuscularly, intradermally, subcutaneously, or intraperitoneally. Suppositories are administered rectally.
[0042] The dosage of the antitumor composition of the present disclosure can be appropriately set depending on the method of use, the age and sex of the patient, the severity of the disease, the dosage and administration time of the antitumor agent (A), other conditions, etc. Although not particularly limited, for example, in a single or divided dose, it is 0.001 mg / kg body weight / day to 100 mg / kg body weight / day, preferably 0.001 mg / kg body weight / day to 50 mg / kg body weight / day.
[0043] The form of the combination of the antitumor composition of the present disclosure and the antitumor agent (A) is not particularly limited. More specifically, for example, the antitumor composition of the present disclosure may be (i) an antitumor composition for use in combination with the antitumor agent (A), (ii) an antitumor composition for use to be administered to a person who is administered the antitumor agent (A) or (iii) an antitumor composition further containing the antitumor agent (A), etc.
[0044] The antitumor composition of (i) includes all embodiments in which it is used in combination with the antitumor agent of (A). For example, it includes embodiments in which it is used to be administered to a person who is administered or has been administered the antitumor agent of (A). In other words, the antitumor composition of (i) includes the antitumor composition of (ii). In addition to this, for example, the antitumor composition of (i) also includes an embodiment in which it is used to prepare an antitumor composition containing not only the compound of (B) or a salt thereof but also the antitumor agent of (A) by mixing with the antitumor agent of (A). In other words, the antitumor composition of (i) includes a composition for preparing the antitumor composition of (iii). In addition to this, for example, the antitumor composition of (i) also includes an embodiment in which it is used as a complete kit together with the antitumor agent of (A). In other words, the antitumor composition of (i) also includes an embodiment in which it is used to constitute a kit (particularly an antitumor kit) by being provided together with the antitumor agent of (A).
[0045] The antitumor composition (ii) is used to be administered to a person who will be administered or has been administered the antitumor agent (A). The person who will be administered the antitumor agent (A) here means a person who will be administered the antitumor agent (A) after or simultaneously with the administration of the antitumor composition of the present disclosure. Also, the person who will be administered the antitumor agent (A) here means a person who will be administered the antitumor agent (A) before the administration of the antitumor composition of the present disclosure. In any of these cases, the amount of time to be left between administration of the anti-tumor composition of the present disclosure and administration of the anti-tumor agent (A) is not particularly limited, so long as the anti-tumor agent (A) and the anti-tumor composition of the present disclosure are administered in combination to achieve a synergistic effect for tumor treatment. For example, there may be no time gap (i.e., simultaneous administration), administration of one agent may be started during administration of the other agent, administration of the other agent may be started immediately after administration of one agent is completed, administration of the other agent may be started several minutes to several tens of minutes after administration of one agent is completed, or administration of the other agent may be started, for example, 1 to 12 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12) hours after administration of the other agent is completed.
[0046] The antitumor composition (iii) is an antitumor composition containing not only the compound (B) or a salt thereof but also the antitumor agent (A). The dosage form of the antitumor composition can be appropriately set in consideration of the dosage form of the antitumor agent (A). For example, the antitumor composition can be prepared by mixing the compound (B) or a salt thereof with the antitumor agent (A) or during the preparation of the antitumor agent (A). For this reason, the dosage form of the antitumor composition (iii) is preferably the same as the dosage form of the antitumor agent (A) used in the preparation.
[0047] The present disclosure also includes a kit comprising an antitumor composition containing an antitumor agent (A) and a compound or a salt thereof (B). Such a kit may be referred to as the "kit of the present disclosure." The kit is preferably an antitumor kit (i.e., a kit for preventing or treating tumors). In addition to the antitumor composition containing the antitumor agent (A) and the compound (B) or a salt thereof, the kit may also appropriately include a more preferable medicine for preventing or treating tumors, an administration device (e.g., a syringe), or an instruction sheet (package insert), etc.
[0048] The present disclosure also includes a method for preventing or treating a tumor, comprising administering to a subject an antitumor agent (A) and a compound (B) or a salt thereof. Such a method for preventing or treating a tumor may be referred to as the "prophylactic or therapeutic method of the present disclosure." The prophylactic or therapeutic method of the present disclosure includes a method for preventing or treating a tumor, comprising separately administering an antitumor agent (A) and an antitumor composition containing a compound (B) or a salt thereof, as well as a method for preventing or treating a tumor, comprising administering the antitumor composition (iii) above. In the former method (a tumor prevention or treatment method including separate administration), the administration schedule of the antitumor agent (A) and the antitumor composition containing the compound (B) or a salt thereof is not particularly limited as long as the antitumor agent (A) and the antitumor composition of the present disclosure are administered in combination to exert a synergistic effect and treat the tumor, and for example, there may be no time gap (i.e., simultaneous administration), administration of one may be started during administration of the other, administration of the other may be started immediately after administration of one is completed, administration of the other may be started several minutes to several tens of minutes after administration of one is completed, or administration of the other may be started, for example, 1 to 12 (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12) hours after administration of one is completed. In addition, either administration may be started first.
[0049] Furthermore, the subject is not particularly limited as long as the subject is in need of tumor treatment.
[0050] In the present disclosure, a tumor is a disease caused by abnormal cell proliferation, and is preferably a malignant tumor (cancer). More specifically, the present invention relates to breast cancer (e.g., invasive ductal carcinoma, ductal carcinoma in situ, inflammatory breast cancer, etc.), prostate cancer (e.g., hormone-dependent prostate cancer, hormone-independent prostate cancer, etc.), pancreatic cancer (e.g., pancreatic ductal carcinoma, etc.), gastric cancer (e.g., papillary adenocarcinoma, mucinous adenocarcinoma, adenosquamous carcinoma, etc.), lung cancer (e.g., non-small cell lung cancer, small cell lung cancer, malignant mesothelioma, etc.), colon cancer (e.g., gastrointestinal stromal tumor, etc.), rectal cancer (e.g., gastrointestinal stromal tumor, etc.), colorectal cancer (e.g., familial colorectal cancer, hereditary nonpolyposis colorectal cancer, gastrointestinal stromal tumor, etc.), small intestinal cancer (e.g., gastrointestinal stromal tumor, etc.), esophageal cancer, duodenal cancer, tongue cancer, pharyngeal cancer (e.g., nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, etc.), salivary gland cancer, brain tumor (e.g., pineal astrocytic tumor, hairy cell tumor, etc.), and cellular astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, etc.), neurilemmoma, liver cancer (e.g., primary liver cancer, extrahepatic bile duct cancer, etc.), kidney cancer (e.g., renal cell carcinoma, transitional cell carcinoma of the renal pelvis and ureter, etc.), bile duct cancer, endometrial cancer, cervical cancer, uterine sarcoma, ovarian cancer (e.g., epithelial ovarian cancer, extragonadal germ cell tumor, ovarian germ cell tumor, ovarian low malignant potential tumor, etc.), bladder cancer, urethral cancer, skin cancer (e.g., intraocular (eye) melanoma, Merkel cell carcinoma, etc.), hemangioma, malignant lymphoma (e.g., non-Hodgkin's lymphoma, Hodgkin's lymphoma, etc.), malignant melanoma, thyroid cancer (e.g., medullary thyroid cancer, etc.), parathyroid cancer, nasal cancer, paranasal sinus cancer, myeloma (e.g., multiple myeloma), bone tumor (e.g., osteosarcoma, Ewing's tumor) , soft tissue sarcoma, etc.), myelodysplastic tumor, myeloproliferative tumor, angiofibroma, retinal sarcoma, penile cancer, testicular tumor, pediatric solid tumor (e.g., Wilms' tumor, pediatric renal tumor, etc.), Kaposi's sarcoma, Kaposi's sarcoma caused by AIDS, maxillary sinus tumor, fibrous histiocytoma, leiomyosarcoma, rhabdomyosarcoma, leukemia (e.g., acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, etc.). Among them, particularly preferred cancer types for application of the antitumor composition, kit, or preventive or therapeutic method of the present disclosure include malignant lymphoma, leukemia, myeloma, breast cancer, gastric cancer, pancreatic cancer, lung cancer, ovarian cancer, etc.
[0051] Note that, in this specification, the term "comprising" includes "consisting essentially of” and "consisting of."
[0052] Also, the various characteristics (properties, structures, functions, etc.) described for each of the above-described embodiments may be combined in any manner in identifying the subject matter encompassed by this disclosure.
Example
[0053] Hereinafter, the subject matter encompassed by this disclosure will be described more specifically, but the subject matter is not limited to the following examples.
[0054] According to the method described in the examples of International Publication No. 2012 / 046825 (particularly Example 24), N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide hydrochloride (white powder) was prepared. This N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide hydrochloride may sometimes be referred to as Compound A below. The obtained white powder of Compound A was used as "raw powder of Compound A" in the following investigations.
[0055] <In vitro growth inhibition test> Example 1: Effect of combination of Compound A and bendamustine on human follicular lymphoma cell line DOHH-2 1) Test substance Compound A was used in the form of the raw powder. Bendamustine used was purchased from Tokyo Chemical Industry Co., Ltd. 2) Cell culture DOHH-2 cells were obtained from Deutsche Sammlung von Mikroorga The cells were purchased from Nismen und Zellkulturen GmbH (DSMZ). The cells were cultured at 37°C and 5% CO2 in RPMI-1640 medium supplemented with 10% inactivated (treated at 56°C for 30 minutes) fetal bovine serum, penicillin, and streptomycin. The cells were harvested and resuspended in a standard manner and seeded at 1000 cells / well in a 96-well plate. The number of cells seeded was determined to be the number at which the linearity of the cell growth curve was obtained up to the 6th day. 3) Drug addition After culturing the cells at 37°C and 5% CO2 for 24 hours, various concentrations of compound A or The medium containing the antitumor agent was added. After stirring the plate, the plate was incubated at 37°C with 5% CO2 for 12 h. The incubation was continued for 0 hours. 4) Cell proliferation inhibition test CellTiter-Fluor Cell Viability Assay (Promega) A cell proliferation inhibition test was carried out using CellTiter-Fl. After adding uorreagent and incubating, the fluorescence intensity was measured using a fluorescence microplate reader at an excitation wavelength of 400 nm and an emission wavelength of 505 nm. 5) Calculation of cell viability The cell survival rate was calculated by subtracting the blank value containing no cells from the measured value for each well and calculating the ratio to the drug-free control. The cell survival rate was then used to calculate the IC 50 The value was calculated. 6) Isobologram analysis The combined effect of Compound A and a combined antitumor agent (bendamustine) was evaluated using the isobologram method. Specifically, the evaluation was performed as follows. IC of compound A at each concentration of antitumor agent 50 The IC value (the concentration that inhibits cell proliferation by 50% compared to the drug-free control) was calculated. The concentration of each antitumor agent was calculated as the IC 50 The partial inhibitory concentration coefficient (FIC) of the antitumor agent was calculated by dividing the IC value of compound A. 50 Values are the IC of compound A alone 50The FIC of compound A was calculated by dividing the IC of antitumor agent at each concentration of compound A 50 The IC value was calculated for each concentration of Compound A. 50 The FIC of compound A was calculated by dividing the value by the antitumor agent. I C 50 IC value of single antitumor agent 50 The FIC of the antitumor agent was calculated by dividing the value by the total antibody titer. The sum of the FICs for each combination was taken as the CI value for each combination. The mean CI and 95% confidence interval were calculated. Details of the calculations are shown in Table 1.
[0056] [Table 1]
[0057] A graph plotting the FIC of each drug (compound A and bendamustine) is shown in Figure 1. In the isobologram, when each plot is located to the upper right, almost on the line, or to the lower left of the line connecting the points where the FIC of each drug is 1, it means that an antagonistic, additive, or synergistic effect is shown, respectively. Since each plot shown in Figure 1 was located to the lower left of the line, it was found that the combined use of compound A and bendamustine showed a synergistic effect in inhibiting DOHH-2 cell proliferation.
[0058] Example 2: Effect of combination of Compound A and bendamustine on human breast cancer cell line MDA-MB-231 1) Test substance Bulk powder was used as Compound A. Bendamustine was purchased from Tokyo Chemical Industry Co., Ltd. 2) Cell proliferation inhibition test MDA-MB-231 cells were purchased from the American Type Culture Collection (ATCC). Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. However, the number of cells seeded was 2000 cells / well. The results of the isobologram analysis are shown in Figure 2. Since each plot shown in Figure 2 was located to the lower left of the straight line, it was found that the combined use of compound A and bendamustine showed a synergistic effect in inhibiting MDA-MB-231 cell proliferation.
[0059] Example 3: Effect of combination of Compound A and decitabine on human acute myeloid leukemia (AML) cell line CMK-86 1) Test substance Bulk powder was used as Compound A. Decitabine was purchased from Tokyo Chemical Industry Co., Ltd. 2) Cell proliferation inhibition test CMK-86 cells were purchased from the Human Science Research Resources Bank. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. However, the number of cells seeded was 12,000 cells / well. The results of the isobologram analysis are shown in Figure 3. Since each plot shown in Figure 3 was located to the lower left of the straight line, it was found that the combined use of compound A and decitabine showed a synergistic effect in inhibiting CMK-86 cell proliferation.
[0060] Example 4: Effect of combination of Compound A and busulfan on human acute myeloid leukemia (AML) cell line MV-4-11 1) Test substance Bulk powder was used as Compound A. Busulfan was purchased from Wako Pure Chemical Industries, Ltd. 2) Cell proliferation inhibition test MV-4-11 cells were purchased from ATCC. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. However, the number of cells seeded was 8000 cells / well. The results of the isobologram analysis are shown in Figure 4. Since each plot shown in Figure 4 was located to the lower left of the straight line, it was found that the combined use of compound A and busulfan showed a synergistic effect in inhibiting MV-4-11 cell proliferation.
[0061] Example 5: Effect of combination of Compound A and lomustine on human chronic myeloid leukemia (CML) cell line K562 1) Test substance Bulk powder was used as Compound A. Lomustine was purchased from Tokyo Chemical Industry Co., Ltd. 2) Cell proliferation inhibition test K562 cells were purchased from the Human Science Research Resources Bank. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. The results of the isobologram analysis are shown in Figure 5. Since each plot shown in Figure 5 was located to the lower left of the straight line, it was found that the combined use of compound A and lomustine showed a synergistic effect in inhibiting K562 cell proliferation.
[0062] Example 6: Effect of combination of Compound A and thiotepa on human lung cancer cell line A549 1) Test substance Bulk powder was used as Compound A. Thiotepa was purchased from Sigma-Aldrich. 2) Cell proliferation inhibition test A549 cells were purchased from the Human Science Research Resources Bank. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. The results of the isobologram analysis are shown in Figure 6. Since each plot shown in Figure 6 was located to the lower left of the straight line, it was found that the combined use of compound A and thiotepa showed a synergistic effect in inhibiting A549 cell proliferation.
[0063] Example 7: Effect of combination of Compound A and lomustine on human pancreatic cancer cell line BxPC-3 1) Test substance Lomustine was purchased from Tokyo Chemical Industry Co., Ltd. Compound A was used in bulk form. 2) Cell proliferation inhibition test BxPC-3 cells were purchased from ATCC. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. The results of the isobologram analysis are shown in Figure 7. Since each plot shown in Figure 7 was located to the lower left of the straight line, it was found that the combined use of Compound A and Lomustine showed a synergistic effect in inhibiting BxPC-3 cell proliferation.
[0064] Example 8: Effect of combination of Compound A and melphalan on human acute myeloid leukemia (AML) cell line KG-1 1) Test substance Bulk powder was used as Compound A. Melphalan was purchased from Sigma-Aldrich. 2) Culture medium and cell passage KG-1 cells were purchased from the Human Science Research Resources Bank. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. However, the number of cells seeded was 8000 cells / well. The results of the isobologram analysis are shown in Figure 8. Since each plot shown in Figure 8 was located to the lower left of the straight line, it was found that the combined use of compound A and melphalan showed a synergistic effect in inhibiting KG-1 cell proliferation.
[0065] Example 9: Effect of combination of Compound A and lomustine on human diffuse large B-cell lymphoma (DLBCL) cell line U2932 1) Test substance Bulk powder was used as Compound A. Lomustine was purchased from Tokyo Chemical Industry Co., Ltd. 2) Cell proliferation inhibition test U2932 cells were purchased from DSMZ. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. However, the number of cells seeded was 2000 cells / well. The results of the isobologram analysis are shown in Figure 9. Since each plot shown in Figure 9 was located to the lower left of the straight line, it was found that the combined use of compound A and lomustine showed a synergistic effect in inhibiting U2932 cell proliferation.
[0066] Example 10: Effect of combination of Compound A and melphalan on human diffuse large B-cell lymphoma (DLBCL) cell line U2932 1) Test substance Bulk powder was used as Compound A. Melphalan was purchased from Sigma-Aldrich. 2) Cell proliferation inhibition test U2932 cells were purchased from DSMZ. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. However, the number of cells seeded was 2000 cells / well. The results of the isobologram analysis are shown in Figure 10. Since each plot shown in Figure 10 was located to the lower left of the straight line, it was found that the combined use of compound A and melphalan showed a synergistic effect in inhibiting U2932 cell proliferation.
[0067] Example 11: Effect of combination of Compound A and melphalan on human acute myeloid leukemia (AML) cell line MV-4-11 1) Test substance Bulk powder was used as Compound A. Melphalan was purchased from Sigma-Aldrich. 2) Cell proliferation inhibition test MV-4-11 cells were purchased from ATCC. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. However, the number of cells seeded was 8000 cells / well. The results of the isobologram analysis are shown in Figure 11. Since each plot shown in Figure 11 was located to the lower left of the straight line, it was found that the combined use of compound A and melphalan showed a synergistic effect in inhibiting MV-4-11 cell proliferation.
[0068] Example 12: Effect of combination of Compound A and lomustine on human gastric cancer cell line MKN45 1) Test substance Bulk powder was used as Compound A. Lomustine was purchased from Tokyo Chemical Industry Co., Ltd. 2) Cell proliferation inhibition test MKN45 cells were purchased from the Human Science Research Resources Bank. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. The results of the isobologram analysis are shown in Figure 12. Since each plot shown in Figure 12 was located to the lower left of the straight line, it was found that the combined use of compound A and lomustine showed a synergistic effect in inhibiting MKN45 cell proliferation.
[0069] Example 13: Effect of combination of Compound A and decitabine on human acute myeloid leukemia (AML) cell line MV-4-11 1) Test substance Bulk powder was used as Compound A. Decitabine was purchased from Tokyo Chemical Industry Co., Ltd. 2) Cell proliferation inhibition test MV-4-11 cells were purchased from ATCC. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. However, the number of cells seeded was 8000 cells / well. The results of the isobologram analysis are shown in Figure 13. Since each plot shown in Figure 13 was located to the lower left of the straight line, it was found that the combined use of compound A and decitabine showed a synergistic effect in inhibiting MV-4-11 cell proliferation.
[0070] Example 14: Effect of combination of Compound A and decitabine on human acute myeloid leukemia (AML) cell line OCI-AML2 1) Test substance Bulk powder was used as Compound A. Decitabine was purchased from Tokyo Chemical Industry Co., Ltd. 2) Cell proliferation inhibition test OCI-AML2 cells were purchased from DSMZ. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. However, the number of cells seeded was 4000 cells / well. The results of the isobologram analysis are shown in Figure 14. Since each plot shown in Figure 14 was located to the lower left of the straight line, it was found that the combined use of compound A and decitabine showed a synergistic effect in inhibiting OCI-AML2 cell proliferation.
[0071] Example 15: Effect of combination of Compound A and cytarabine on human acute myeloid leukemia (AML) cell line MV-4-11 1) Test substance Bulk powder was used as Compound A. Cytarabine was purchased from Wako Pure Chemical Industries, Ltd. 2) Cell proliferation inhibition test MV-4-11 cells were purchased from ATCC. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. However, the number of cells seeded was 8000 cells / well. The results of the isobologram analysis are shown in Figure 15. Since each plot shown in Figure 15 was located to the lower left of the straight line, it was found that the combined use of compound A and cytarabine showed a synergistic effect in inhibiting MV-4-11 cell proliferation.
[0072] Example 16: Effect of combination of Compound A and bendamustine on human breast cancer cell line BT-474 1) Test substance Bulk powder was used as Compound A. Bendamustine was purchased from Tokyo Chemical Industry Co., Ltd. 2) Cell proliferation inhibition test BT-474 cells were purchased from ATCC. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. However, the number of cells seeded was 8000 cells / well. The results of the isobologram analysis are shown in Figure 16. Since each plot shown in Figure 16 was located to the lower left of the straight line, it was found that the combined use of compound A and bendamustine showed a synergistic effect in inhibiting cell proliferation by BT-474.
[0073] Example 17: Effect of combined use of Compound A and melphalan in human multiple myeloma cell line RPMI 8226 1) Test substance Bulk powder was used as Compound A. Melphalan was purchased from Sigma-Aldrich. 2) Cell proliferation inhibition test RPMI 8226 cells were purchased from ATCC. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. However, the number of cells seeded was 4000 cells / well. The results of the isobologram analysis are shown in Figure 17. Since each plot shown in Figure 17 was located to the lower left of the straight line, it was found that the combined use of compound A and melphalan was effective in inhibiting RPMI 8226 cell proliferation. A synergistic effect was found to be observed.
[0074] Example 18: Effect of combination of Compound A and venetoclax on human acute myeloid leukemia (AML) cell line KG-1 1) Test substance Compound A was used in its original form. Venetoclax was purchased from Elsie Laboratories. was used. 2) Cell proliferation inhibition test KG-1 cells were purchased from the Human Science Research Resources Bank. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. However, the number of cells seeded was 8000 cells / well. The results of the isobologram analysis are shown in Figure 18. Since each plot shown in Figure 18 was located to the lower left of the straight line, it was found that the combined use of compound A and venetoclax showed a synergistic effect in inhibiting KG-1 cell proliferation.
[0075] Example 19: Effect of combination of Compound A and Ranimustine on human chronic myeloid leukemia (CML) cell line K562 1) Test substance Bulk powder was used as Compound A. Ranimustine was purchased from Toronto Research Chemicals. 2) Cell proliferation inhibition test K562 cells were purchased from the Human Science Research Resources Bank. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. The results of the isobologram analysis are shown in Figure 19. Since each plot shown in Figure 19 was located to the lower left of the straight line, it was found that the combined use of compound A and ranimustine showed a synergistic effect in inhibiting K562 cell proliferation.
[0076] Example 20: Efficacy of the combination of Compound A and thiotepa in human ovarian cancer cell line SK-OV-3 Fruit 1) Test substance Bulk powder was used as Compound A. Thiotepa was purchased from Sigma-Aldrich. 2) Cell proliferation inhibition test SK-OV-3 cells were purchased from ATCC. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. The results of the isobologram analysis are shown in Figure 20. Since each plot shown in Figure 20 was located to the lower left of the straight line, it was found that the combined use of compound A and thiotepa showed a synergistic effect in inhibiting SK-OV-3 cell proliferation.
[0077] Example 21: Combination effect of Compound A and ibrutinib in human acute myeloid leukemia (AML) cell line MV-4-11 1) Test substance Bulk powder was used as Compound A. Ibrutinib was purchased from Medchem Express. 2) Cell proliferation inhibition test MV-4-11 cells were purchased from ATCC. Cell culture, drug addition, and A cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed. The number of cells seeded was 8000 cells / well. The results of the isobologram analysis are shown in Figure 21. Since each plot shown in FIG. 21 was located to the lower left of the straight line, it was found that the combined use of compound A and ibrutinib exhibited a synergistic effect in inhibiting MV-4-11 cell proliferation.
[0078] Example 22: Compound A and decitabine in human myelodysplastic syndrome cell line SKM-1 Combined effect of 1) Test substance Bulk powder was used as Compound A. Decitabine was purchased from Tokyo Chemical Industry Co., Ltd. 2) Cell proliferation inhibition test SKM-1 cells were obtained from the JCRB Cell Bank ( The cells were purchased from JCRB. The cell survival rate was calculated and isobologram analysis was performed. The number of cells seeded was 8,000 cells. s / well. The results of the isobologram analysis are shown in Figure 22. Since each plot shown in Figure 22 was located to the lower left of the straight line, it was found that the combined use of compound A and decitabine showed a synergistic effect in inhibiting the cell proliferation of SKM-1.
[0079] Example 23: Effect of combination of Compound A and erlotinib on human lung cancer cell line A549 1) Test substance Bulk powder was used as Compound A. Erlotinib was purchased from Wako Pure Chemical Industries, Ltd. 2) Cell proliferation inhibition test A549 cells were purchased from the Japan Human Science Research Resources Bank. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed. However, the number of cells seeded was 1000 cells / well. The results are shown in Figure 23. Since each plot shown in Figure 23 was located to the lower left of the straight line, it was found that the combined use of compound A and erlotinib exhibited a synergistic effect in inhibiting A549 cell proliferation.
[0080] Example 24: Combination effect of Compound A and gefitinib in human lung cancer cell line A549 1) Test substance Bulk powder was used as Compound A. Gefitinib was purchased from Wako Pure Chemical Industries, Ltd. 2) Cell proliferation inhibition test A549 cells were purchased from the Japan Human Science Research Resources Bank. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed. However, the number of cells seeded was 1000 cells / well. The results are shown in Figure 24. Since each plot shown in Figure 24 was located to the lower left of the straight line, it was found that the combined use of compound A and gefitinib exhibited a synergistic effect in inhibiting A549 cell proliferation.
[0081] Example 25: Combination effect of Compound A and gefitinib in human lung cancer cell line HCC 827 1) Test substance Bulk powder was used as Compound A. Gefitinib was purchased from Wako Pure Chemical Industries, Ltd. 2) Cell proliferation inhibition test HCC 827 cells were purchased from ATCC. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. However, the number of cells seeded was 4000 cells / well. The results of the isobologram analysis are shown in FIG. Since each plot shown in FIG. 25 was located to the lower left of the straight line, it was found that the combined use of Compound A and gefitinib exhibited a synergistic effect in inhibiting the cell proliferation of HCC 827.
[0082] Example 26: Combination effect of Compound A and imatinib in human chronic myeloid leukemia (CML) cell line K562 1) Test substance Bulk powder was used as Compound A. Imatinib was purchased from Wako Pure Chemical Industries, Ltd. 2) Cell proliferation inhibition test K562 cells were purchased from the Japan Human Science Research Resources Bank. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed. However, the number of cells seeded was 1000 cells / well. The results are shown in Figure 26. Since each plot shown in Figure 26 was located to the lower left of the straight line, it was found that the combined use of Compound A and imatinib exhibited a synergistic effect in inhibiting the cell proliferation of K562.
[0083] Example 27: Combination effect of Compound A and axitinib in human renal cancer cell line ACHN 1) Test substance Bulk powder was used as Compound A. Axitinib was purchased from Selleck Biotech. 2) Cell proliferation inhibition test ACHN cells were obtained from Otsuka Pharmaceutical TRC. Cell culture, drug addition, and A cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed. However, the number of cells seeded was 8000 cells / well. The results of the isobologram analysis are shown in Figure 27. Since each plot shown in FIG. 27 was located to the lower left of the straight line, it was found that the combined use of compound A and axitinib exhibited a synergistic effect in inhibiting ACHN cell proliferation.
[0084] Example 28: Interaction of Compound A with Lapatinib in Human Breast Cancer Cell Line MDA-MB-453 Combined Effects 1) Test substance Bulk powder was used as Compound A. Lapatinib was purchased from LC Laboratories. 2) Cell proliferation inhibition test MDA-MB-453 cells were purchased from ATCC. Cell culture and drug The addition of 8000 cells / well was used for the cell growth inhibition test, the cell viability calculation, and the isobologram analysis. The isobologram analysis results are shown in Figure 28. Since each plot shown in Figure 28 was located to the lower left of the straight line, it was found that the combined use of compound A and lapatinib showed a synergistic effect in inhibiting cell proliferation of MDA-MB-453.
[0085] Example 29: Combination effect of Compound A and Lenvatinib in human hepatoma cell line Hep G2 1) Test substance Compound A was used in its original form. Lenvatinib was purchased from Funakoshi Co., Ltd. 2) Cell proliferation inhibition test Hep G2 cells were purchased from ATCC. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed in the same manner as in Example 1. However, the number of cells seeded was 2000 cells / well. The results of the isobologram analysis are shown in FIG. Since each plot shown in FIG. 29 was located to the lower left of the straight line, it was found that the combined use of compound A and lenvatinib exhibited a synergistic effect in inhibiting the proliferation of Hep G2 cells.
[0086] Example 30: Efficacy of combination of Compound A and lapatinib in human breast cancer cell line SK-BR-3 Fruit 1) Test substance Bulk powder was used as Compound A. Lapatinib was purchased from LC Laboratories. 2) Cell proliferation inhibition test SK-BR-3 cells were purchased from ATCC. Cell culture, drug addition, and A cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed. However, the number of cells seeded was 4000 cells / well. The results of the isobologram analysis are shown in Figure 30. Since each plot shown in FIG. 30 was located to the lower left of the straight line, it was found that the combined use of compound A and lapatinib exhibited a synergistic effect in inhibiting the cell proliferation of SK-BR-3.
[0087] Example 31: Combination effect of Compound A and Afatinib in human lung cancer cell line A549 1) Test substance Bulk powder was used as Compound A. Afatinib was purchased from Tokyo Chemical Industry Co., Ltd. 2) Cell proliferation inhibition test A549 cells were purchased from the Japan Human Science Research Resources Bank. Cell culture, drug addition, cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed. However, the number of cells seeded was 1000 cells / well. The results are shown in Figure 31. Since each plot shown in Figure 31 was located to the lower left of the straight line, it was found that the combined use of compound A and afatinib exhibited a synergistic effect in inhibiting A549 cell proliferation.
[0088] Example 32: Compound A in human acute myeloid leukemia (AML) cell line MV-4-11 Combined effect of gilteritinib 1) Test substance Bulk powder was used as Compound A. Gilteritinib was purchased from Cayman Chemical Company. 2) Cell proliferation inhibition test MV-4-11 cells were purchased from ATCC. Cell culture, drug addition, and A cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed. However, the number of cells seeded was 8000 cells / well. The results of the isobologram analysis are shown in Figure 32. Since each plot shown in FIG. 32 was located to the lower left of the straight line, it was found that the combined use of compound A and gilteritinib exhibited a synergistic effect in inhibiting MV-4-11 cell proliferation.
[0089] Example 33: Combination of Compound A and 5-FU in human head and neck (pharyngeal) cancer cell line FaDu Use effect 1) Test substance Bulk powder was used as Compound A. 5-FU was purchased from Sigma-Aldrich Co., Ltd. 2) Cell proliferation inhibition test FaDu cells were purchased from ATCC. Cell culture, drug addition, and cell proliferation were performed in the same manner as in Example 1. A proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed. However, the number of cells seeded was 1000 cells / well. The results of the isobologram analysis are shown in Figure 33. Since each plot was located to the lower left of the straight line, it was found that the combined use of compound A and 5-FU exhibited a synergistic effect in inhibiting FaDu cell proliferation.
[0090] Comparative Example 1: Effect of combination of Compound A and vincristine on human diffuse large B-cell lymphoma cell line OCI-Ly18 1) Test substance Bulk powder was used as Compound A. Vincristine was purchased from Wako Pure Chemical Industries, Ltd. 2) Cell proliferation inhibition test OCI-Ly18 cells were purchased from DSMZ. Cell culture and drug addition were performed in the same manner as in Example 1. A cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed. However, the number of cells seeded was 16,000 cells / well. The results of the isobologram analysis are shown in Figure 34. Since each plot shown in Figure 34 was located almost on a straight line, it was found that the combined use of compound A and vincristine only showed an additive effect in inhibiting the cell proliferation of OCI-Ly18.
[0091] Comparative Example 2: Effect of combined use of Compound A and docetaxel on human breast cancer cell line BT-474 1) Test substance Bulk powder was used as Compound A. Docetaxel was purchased from Wako Pure Chemical Industries, Ltd. 2) Cell proliferation inhibition test BT-474 cells were purchased from ATCC. Cell culture, drug addition, and cellular A cell proliferation inhibition test, calculation of cell viability, and isobologram analysis were performed. However, the number of cells seeded was 8000 cells / well. The results of the isobologram analysis are shown in Figure 35. Since each plot shown in FIG. 35 was located almost on a straight line, it was found that the combined use of Compound A and docetaxel only exhibited an additive effect in inhibiting the cell proliferation of BT-474.
[0092] Example 34: Combination effect of Compound A and bendamustine in human diffuse large B-cell lymphoma (DLBCL) cell line OCI-Ly7 1) Test substance Bulk powder was used as Compound A. Bendamustine was purchased from Tokyo Chemical Industry Co., Ltd. 2) Cell proliferation inhibition test OCI-Ly7 cells were purchased from DSMZ. Cell culture, drug addition, cell proliferation inhibition test, and calculation of cell viability were performed in the same manner as in Example 1. However, the number of cells seeded was 8000 cells / well. The results are shown in Table 2.
[0093] [Table 2]
[0094] 3) Statistical analysis Combination index (CI) and 95% confidence intervals were calculated using SAS software Release 9.3 (SAS Institute JAPAN). CI=0.67, 95% confidence interval 0.37 to 0.96. A CI greater than 1, equal to 1, or less than 1 indicates antagonistic, additive, or synergistic effects, respectively. Therefore, the combination of compound A and bendamustine is OCI-Ly 7 It was found that they exhibited a synergistic effect in inhibiting cell proliferation.
[0095] Example 35: Effect of combination of Compound A and bendamustine on human mantle cell lymphoma cell line REC-1 1) Test substance Bulk powder was used as Compound A. Bendamustine was purchased from Tokyo Chemical Industry Co., Ltd. 2) Cell proliferation inhibition test The REC-1 cells were purchased from DSMZ. Cell culture, drug addition, cell growth inhibition test, and calculation of cell viability were performed in the same manner as in Example 1. However, the number of seeded cells was 8000 cells / well. Using the obtained results, the combination index (CI) and 95% confidence interval were calculated in the same manner as in Example 35. CI = 0.65, and the 95% confidence interval was from 0.34 to 0.96. Therefore, it was found that the combined use of Compound A and vincristine showed a synergistic effect in inhibiting the growth of REC-1 cells.
[0096] <In Vivo Antitumor Effect Test> Example 36: Effect of combination of Compound A and cyclophosphamide on human diffuse large B-cell lymphoma cell line OCI-Ly7 1) Test Substances The raw powder of Compound A was used. Cyclophosphamide (Endoxan[trademark] for injection 100 mg) was purchased from Shionogi & Co., Ltd. and used. 2) Preparation of Test Substances Compound A was suspended in a 1% hypromellose solution to prepare a test substance suspension of 10 mg / mL (for a dosing solution of 100 mg / kg). The test substance suspension was diluted with a 1% hypromellose solution to prepare test substance suspensions of 3 mg / mL (for a dosing solution of 30 mg / kg) and 1 mg / mL (for a dosing solution of 10 mg / kg). Also, 20 mL of physiological saline was added to 100 mg of commercially available Endoxan for injection and dissolved to prepare a 5 mg / mL solution (for a dosing solution of 50 mg / kg) immediately before use, which was used as cyclophosphamide. 3) Cells OCI-Ly7 was obtained from DSMZ. The cells were cultured under the conditions of 37°C and 5% CO2 using RPMI1640 medium supplemented with 10% heat-inactivated (treated at 56°C for 30 minutes) fetal bovine serum. The collected cells were suspended in serum-free RPMI1640 medium at 1.5×10 8 cells / mL. 4) Animals Five-week-old female SCID mice (CB-17 / Icr-scid / scid Jcl, CLEA Japan, Inc.) were used. The female SCID mice were kept under specific pathogen-free (SPF) conditions throughout the study period, and were given standard feed and drinking water. The cell suspension was then added at 3 × 10 7 The cells / body were subcutaneously transplanted into the right axilla of 6-week-old SCID mice. Using tumor volume as an index, the mice were divided into groups by stratified random sampling using SAS software R9.3 (SAS Institute Japan). 5) Administration and Measurement Administration began the day after grouping (Day 2), with Compound A orally administered once a day for 14 consecutive days, and cyclophosphamide intraperitoneally administered once every 3 or 4 days, a total of 4 times. In order to match the combination group, the control group was administered the solvent for each drug, and the single drug treatment group was administered the solvent for the combination drug, in the same manner as the combination treatment group. All animals were administered orally for 14 consecutive days, and intraperitoneally once every 3 or 4 days (a total of 4 times). Each group (N=8) was treated as follows. (1) Control (solvent control) group: 1% hypromellose solution, saline (2) Compound A (10 mg / kg) treatment group: Compound A 10 mg / kg (once a day, every day Oral administration for 14 days) (3) Compound A (30 mg / kg) treatment group: Compound A 30 mg / kg (administered orally once a day for 14 consecutive days) (4) Compound A (100 mg / kg) treatment group: Compound A 100 mg / kg (administered orally once a day for 14 consecutive days) (5) Cyclophosphamide (50 mg / kg) group: Cyclophosphamide 50 mg / kg (intraperitoneally administered on days 2, 5, 9, and 12) (6) Combination Group 1: Compound A 10 mg / kg (oral administration once a day for 14 consecutive days) + cyclophosphamide 50 mg / kg (intraperitoneal administration on Days 2, 5, 9, and 12) (7) Combination Group 2: Compound A 30 mg / kg (oral administration once a day for 14 consecutive days) + cyclophosphamide 50 mg / kg (intraperitoneal administration on Days 2, 5, 9, and 12) (8) Combination group 3: Compound A 100 mg / kg (orally administered once a day for 14 consecutive days) + Cyclophosphamide 50mg / kg (intraperitoneally administered on days 2, 5, 9, and 12) Body weight and tumor diameter were measured over time using an electronic balance and electronic calipers. Tumor volume was calculated as (long diameter × [short diameter] 2 The tumor volume was calculated from the formula: tumor volume on the day of measurement x 0.5. The calculated tumor volume value was used to calculate the relative tumor volume (ratio of tumor volume on the day of measurement to the baseline tumor volume on Day 1). The time from the day of grouping (Day 1) until the relative tumor volume of each animal reached 1600% was estimated from the data on the measurement day close to the time when the relative tumor volume reached 1600%. Tumor growth delay (TGD) was calculated as the difference in the median time until the relative tumor volume reached 1600% for the treatment group and the control group. Furthermore, the tumor growth delay rate (%TGD) was calculated according to the following formula. %TGD = {(TC) / C} × 100 however, T: Median time to reach 1600% relative tumor volume for treatment group C: Median time to reach 1600% relative tumor volume for the control group 6) Statistical analysis To examine the effect of compound A monotherapy on tumor growth delay, a Steel test (two-tailed) was performed on the control group (group 1) and compound A monotherapy groups (groups 2, 3, and 4) based on the time it took for each animal's relative tumor volume to reach 1600%. To examine the effect of cyclophosphamide monotherapy on tumor growth delay, a Wilcoxon rank-sum test (two-tailed) was performed between the control group (group 1) and the cyclophosphamide monotherapy groups (group 5) based on the time it took for each animal's relative tumor volume to reach 1600%. To investigate the effect of the combination treatment group of Compound A and cyclophosphamide on tumor growth delay, the time until the relative tumor volume reached 1600% was compared between the combination treatment group (group 6) and each single drug treatment group (groups 2 and 5), the combination treatment group (group 7) and each single drug treatment group (groups 3 and 5), and the combination treatment group (group 8) and each single drug treatment group (groups 4 and 5) were compared using Steel test (two-sided). The combination treatment group was deemed to have a combination effect when it was significant compared to each single drug treatment group. In addition, when significant differences were observed in the combination treatment groups compared to each single-agent treatment group, two-way ANOVA (two-tailed, factors: group and dose) was performed between the compound A treatment groups (groups 1 and 2) and the cyclophosphamide treatment groups (groups 5 and 6), between the compound A treatment groups (groups 1 and 3) and the cyclophosphamide treatment groups (groups 5 and 7), and between the compound A treatment groups (groups 1 and 4) and the cyclophosphamide treatment groups (groups 5 and 8) to examine interaction effects. 7) Results The time to 1600% relative tumor volume, which was the evaluation endpoint, was 12.7 days (median time) in the control group. The tumor growth retardation rates (%) for cyclophosphamide 50 mg / kg were 3.5%, 81.1%, and 147.6%, respectively. The tumor growth retardation rates (%) for cyclophosphamide 50 mg / kg were 83.9%. Monotherapy with Compound A at 30 or 100 mg / kg or cyclophosphamide at 50 mg / kg was shown to be effective. In the combination treatment, compound A 10mg / kg + cyclophosphamide 50mg / kg group, compound The tumor growth retardation rates (%) in the compound A 30mg / kg + cyclophosphamide 50mg / kg group and the compound A 100mg / kg + cyclophosphamide 50mg / kg group were >287.0%, >293.7%, and >293.7%, respectively. When compound A was administered in combination with cyclophosphamide, a significant interaction with the combination effect was observed, and the combination effect was significantly synergistic. In the combination treatment, the tumor shrank at compound A 10mg / kg or more, and In addition, the compound A was used in combination with cyclophosphamide at 30 or In the group administered 100 mg / kg, no tumor regrowth was observed during the observation period after administration (Day 16 to Day 51) (Table 3, Figure 36, Figure 37, Figure 38). 8) Conclusion Monotherapy with Compound A at 30 or 100 mg / kg, cyclophosphamide at 50 mg / kg, and combination therapy with Compound A at 10, 30, or 100 mg / kg and cyclophosphamide at 50 mg / kg were shown to have significant antitumor activity in SCID mice implanted with OCI-Ly7. The combination treatments were well tolerated and showed significant synergistic effects.
[0097] [Table 3]
[0098] Example 37: Combination effect of Compound A and lapatinib in human breast cancer cell line MDA-MB-453 1) Test substance Compound A was used in its raw form. Lapatinib was purchased from LC Laboratories as Lapatinib, Di-p-Toluenesulfonate Salt. did. 2) Preparation of test substances Compound A was suspended in 1% hypromellose solution at 20 mg / mL (suspension for preparing single agent solution). Test substance suspensions of 10 mg / mL (100 mg / kg administration solution), 6 mg / mL (30 mg / kg administration solution suspension), and 3 mg / mL (30 mg / kg administration solution) were prepared. Lapatinib was suspended in 1% hypromellose solution to prepare a 20 mg / mL suspension for preparing the lapatinib 100 mg / kg combination administration solution. The 20 mg / mL suspension was diluted with 1% hypromellose solution to prepare a 10 mg / mL suspension for preparing the 100 mg / kg single agent administration. The administration solution for the combination group was prepared by mixing a 6 mg / mL suspension of compound A and a 20 mg / mL suspension of lapatinib in a 1:1 ratio, or by mixing a 20 mg / mL suspension of compound A and a 20 mg / mL suspension of lapatinib in a 1:1 ratio. 3) Cell MDA-MB-453 was obtained from ATCC. The cells were cultured at 37°C and 5% CO2 in RPMI1640 medium supplemented with 10% inactivated fetal bovine serum (treated at 56°C for 30 minutes). The collected cells were cultured in serum-free RPMI1640 medium at a concentration of 1.0 × 10 8 The cells were suspended at 1000 cells / mL. 4)Animals Five-week-old female NOD-SCID mice (NOD.CB17-Prkdcscid / J, Charles River Laboratories Japan) were used. The female NOD-SCID mice were bred in the same manner as in Example 36. The cell suspension was added at 2 × 10 7 The mice were subcutaneously transplanted at a dose of 1000 sera / body into the right axilla of 6-week-old NOD-SCID mice, and the mice were divided into groups based on the tumor volume in the same manner as in Example 36. 5) Administration and Measurement Administration began the day after group division (Day 2), and Compound A and lapatinib were orally administered once a day for 28 consecutive days. Each group (N=8) was treated as follows. (1) Control (solvent control) group: 1% hypromellose solution (2) Compound A (30 mg / kg) treatment group: Compound A 30 mg / kg (administered orally once a day for 28 consecutive days) (3) Compound A (100 mg / kg) treatment group: Compound A 100 mg / kg (administered orally once a day for 28 consecutive days) (4) Lapatinib (100 mg / kg) treatment group: Lapatinib 100 mg / kg (administered orally once daily for 28 days) (5) Combination group 1: Compound A 30 mg / kg (once a day, orally administered for 28 consecutive days) + lapatinib 100 mg / kg (once a day, orally administered for 28 consecutive days) (6) Combination group 2: Compound A 100 mg / kg (administered orally once a day for 28 consecutive days) + Lapatinib 100mg / kg (administered orally once daily for 28 days) Measurements were performed in the same manner as in Example 36, and tumor growth delay was calculated and statistically analyzed. 6) Results The time to 200% relative tumor volume, which was the evaluation endpoint, was 22.8 days (median time) in the control group. The tumor growth delay rates (%) were 72.4% and >334.2%, respectively. The tumor growth retardation rate (%) at 100 mg / kg was 50.0%. 00mg / kg or lapatinib 100mg / kg monotherapy was shown to be effective. was shown. In the combination treatment, compound A 30mg / kg + lapatinib 100mg / kg group and compound A The tumor growth retardation rate (%) in both the 100 mg / kg + lapatinib 100 mg / kg groups was >334.2%. When compound A 30 mg / kg was administered in combination with lapatinib 100 mg / kg, a significant interaction was observed with the combination effect, and the combination effect was significantly synergistic. In the combination treatment, both doses of compound A resulted in complete tumor regression. Furthermore, compound A 100 mg In the 100 mg / kg + lapatinib 100 mg / kg group, no tumor regrowth was observed up to 2 months after the end of the combination treatment (Table 4, Figure 39, Figure 40). 7) Conclusion Monotherapy with Compound A at 30 or 100 mg / kg, Lapatinib at 100 mg / kg, and combination therapy with Compound A at 30 or 100 mg / kg and Lapatinib at 100 mg / kg were shown to have significant antitumor activity in NOD-SCID mice implanted with MDA-MB-453 tumors. The combination therapy was well tolerated and showed significant synergistic effects.
[0099] [Table 4]
[0100] Example 38: Effect of combination of Compound A and bendamustine on human diffuse large B-cell lymphoma cell line OCI-Ly7 1) Test substance The bulk powder of compound A was used. Bendamustine was purchased from Tokyo Chemical Industry Co., Ltd. I purchased and used stine hydrochloride hydrate. 2) Preparation of test substances Compound A was suspended in 1% hypromellose solution to prepare a 3 mg / mL (30 mg / kg administration solution) suspension of the test substance. Bendamustine was dissolved in saline to prepare a 1.5 mg / mL solution (15 mg / kg administration solution) just before use. 3) Cell OCI-Ly7 was obtained from DSMZ. The cells were cultured at 37°C and 5% CO2 in RPMI1640 medium supplemented with 10% inactivated fetal bovine serum (treated at 56°C for 30 minutes). The collected cells were cultured in serum-free RPMI1640 medium at a concentration of 1.5 × 10 8 The cells were suspended at 1000 cells / mL. 4)Animals Five-week-old female SCID mice (CB-17 / Icr-scid / scid Jcl, manufactured by CLEA Japan, Inc.) were used. The female SCID mice were bred in the same manner as in Example 36. The cell suspension was added at 3 × 10 7 The cells / body were subcutaneously transplanted into the right axilla of 6-week-old SCID mice, and the mice were divided into groups in the same manner as in Example 36 based on the tumor volume. 5) Administration and Measurement Administration began the day after grouping (Day 2), and Compound A was orally administered once a day for 14 consecutive days, while bendamustine was intraperitoneally administered five times in total on Days 2, 3, 4, 5, and 6. In order to match the combination group, the control group was administered the solvent for each drug, and the single drug administration group was administered the solvent for the combination drug in the same manner as the combination group. All animals were orally administered daily for 14 consecutive days, and intraperitoneally administered on Days 2, 3, 4, 5, and 6 (a total of five times). Each group (N=6) was treated as follows. (1) Control (solvent control) group: 1% hypromellose solution, saline (2) Compound A (30 mg / kg) treatment group: Compound A 30 mg / kg (administered orally once a day for 14 consecutive days) (3) Bendamustine (15 mg / kg) treatment group: Bendamustine 15 mg / kg (intraperitoneally administered on days 2, 3, 4, 5, and 6) (4) Combination group: Compound A 30 mg / kg (oral administration once a day for 14 consecutive days) + bendamustine 15 mg / kg (intraperitoneal administration on days 2, 3, 4, 5, and 6) Measurements were performed in the same manner as in Example 36, and tumor growth delay was calculated and statistically analyzed. 6) Results The time to 1600% relative tumor volume, which was the evaluation endpoint, was 15.5 days (median time) in the control group. The tumor growth retardation rate (%) was 54.2%. (%) was 56.5%. Monotherapy with 30 mg / kg of compound A or 15 mg / kg of bendamustine was shown to be effective. In combination treatment, tumor growth in the compound A 30mg / kg + bendamustine 15mg / kg group The delay rate (%) was >222.6%. When compound A was administered in combination with bendamustine, a significant interaction was observed with the combination effect, and the combination effect was significantly synergistic. Furthermore, the combination treatment resulted in complete tumor regression (Table 5, Figure 41). 7) Conclusion Monotherapy with Compound A (30 mg / kg), Bendamustine (15 mg / kg), and combination therapy with Compound A (30 mg / kg) and Bendamustine (15 mg / kg) showed significant antitumor activity in SCID mice implanted with OCI-Ly7. The combination therapy was well tolerated and showed significant synergistic effects.
[0101] [Table 5]
[0102] Example 39: Effect of combination of Compound A and Rituximab on human diffuse large B-cell lymphoma cell line OCI-Ly7 1) Test substance The bulk powder of Compound A was used. Rituximab (Rituxan [trademark] 100 mg / 10 mL) was purchased from Genentech, Inc. and used. 2) Preparation of test substances Compound A was suspended in 1% hypromellose solution and administered at 3 mg / mL (30 mg / kg administration solution). Rituximab was diluted with physiological saline to prepare a 1 mg / mL solution (10 mg / kg administration solution) immediately before use. 3) Cell OCI-Ly7 was obtained from DSMZ. The cells were cultured at 37°C and 5% CO2 in RPMI1640 medium supplemented with 10% inactivated fetal bovine serum (treated at 56°C for 30 minutes). The collected cells were cultured in serum-free RPMI1640 medium at a concentration of 1.5 × 10 8 The cells were suspended at 1000 cells / mL. 4)Animals Five-week-old female nude mice (BALB / c Slc-nu / nu, manufactured by Japan SLC Co., Ltd.) were used. The female nude mice were bred in the same manner as in Example 36. The cell suspension was added at 3 × 10 7 The cells / body were subcutaneously transplanted into the right axilla of 6-week-old nude mice, and the mice were divided into groups in the same manner as in Example 36 based on the tumor volume. 5) Administration and Measurement Administration began the day after group allocation (Day 2), and Compound A was orally administered once a day for 21 consecutive days. Rituximab was administered intraperitoneally a total of three times on days 2, 9, and 16. To match the combination group, the control group was administered the solvent for each drug, and the single drug administration group was administered the solvent for the combination drug in the same manner as the combination group. All animals were administered orally every day for 21 days, and intraperitoneally on days 2, 9, and 16 (a total of three times). Each group (N=6) was treated as follows. (1) Control (solvent control) group: 1% hypromellose solution, saline (2) Compound A (30 mg / kg) treatment group: Compound A 30 mg / kg (administered orally once a day for 21 consecutive days) (3) Rituximab treatment group: Rituximab 10mg / kg (intraperitoneally administered on days 2, 9, and 16) (4) Combination group: Compound A 30 mg / kg (administered orally once a day for 21 days) + Tuximab 10mg / kg (intraperitoneal administration on days 2, 9, and 16) Measurements were performed in the same manner as in Example 36, and tumor growth delay was calculated and statistically analyzed. 6) Results The time to 600% relative tumor volume, which was the evaluation endpoint, was 16.3 days (median time) in the control group. In monotherapy, compound A at 30 mg / kg significantly reduced tumor growth. The tumor growth delay rate (%) of rituximab 10 mg / kg was 73.9%. ) was 74.2%. Monotherapy with Compound A 30 mg / kg or Rituximab 10 mg / kg was shown to be effective. In combination treatment, the tumor growth delay rate (%) of the compound A 30 mg / kg + rituximab 10 mg / kg group was >421.5%. When compound A was administered in combination with rituximab, a significant interaction with the combination effect was observed, and the combination effect was significantly synergistic. In addition, the combination treatment resulted in complete tumor regression (Table 6, Figure 42). 7) Conclusion Monotherapy with Compound A (30 mg / kg), Rituximab (10 mg / kg), and combination therapy with Compound A (30 mg / kg) and Rituximab (10 mg / kg) showed significant antitumor activity in nude mice implanted with OCI-Ly7. The combination therapy was well tolerated and showed significant synergistic effects.
[0103] [Table 6]
[0104] Example 40: Effect of combination of Compound A and decitabine on human acute myeloid leukemia (AML) cell line KG-1 1) Test substance The bulk powder of Compound A was used. Decitabine (5-aza-2′-deoxycytidine) was purchased from Tokyo Chemical Industry Co., Ltd. 2) Preparation of test substances Compound A was suspended in 1% hypromellose solution to prepare a 3 mg / mL compound A 30 mg / kg administration solution. Decitabine was diluted with saline to prepare a 0.1 mg / mL decitabine 1 mg / kg dosing solution was prepared. 3) Cell KG-1 was obtained from the Human Science Research Resources Bank. The cells were cultured at 37°C and 5% CO2 in RPMI1640 medium supplemented with 10% inactivated (treated at 56°C for 30 minutes) fetal bovine serum. The collected cells were cultured at 2.5 × 10 8 The cells were suspended at 1000 cells / mL. 4)Animals Five-week-old female SCID mice (CB-17 / Icr-scid / scid Jcl, manufactured by CLEA Japan, Inc.) were used. The female SCID mice were bred in the same manner as in Example 36. The cell suspension was added at 5 × 10 7 The cells / body were subcutaneously transplanted into the right axilla of 6-week-old SCID mice, and the mice were divided into groups in the same manner as in Example 36 based on the tumor volume. 5) Administration and Measurement Administration began the day after group division (Day 2), and tumor size and body weight were measured and evaluated on the day after the 21-day administration ended (Day 23). Each group (N=8) was treated as follows. To match the combination groups, the control group was treated with the solvent for each drug, and the single drug administration group was treated with the combined drug. The solvent was administered in the same manner as in the combination group. (1) Control (solvent control) group: 1% hypromellose solution, saline (2) Compound A treatment group: Compound A 30 mg / kg (oral administration once a day for 21 consecutive days) (3) Decitabine treatment group: Decitabine 1 mg / kg (intraperitoneal administration on days 2, 5, 9, 12, 16, and 19) (4) Combination group: Compound A 30 mg / kg (oral administration once a day for 21 consecutive days) + decitabine 1 mg / kg (intraperitoneal administration on days 2, 5, 9, 12, 16, and 19) Body weight and tumor diameter were measured over time using an electronic balance and electronic calipers. Tumor volume was calculated as (long diameter × [short diameter] 2 × 0.5). Antitumor activity was expressed as the ratio of relative tumor volume of each treatment group to the control group (T / C%). T / C% on day 23 was calculated for each group as the relative tumor volume on day 23 [(tumor volume on day 23 [Tumor volume on Day 1 of each group x 100] / mean tumor volume on Day 23 of the control group Tumor volume [(tumor volume on Day 23 in the control group / tumor volume on Day 1 in the control group It was calculated using the formula: [volume] × 100 × 100. 6) Statistical analysis To investigate the effect of the combination of compound A and decitabine (group 4) on the relative tumor volume (Day 23) compared to compound A alone (group 2) and decitabine alone (group 3), a Dunnett test (two-tailed) was performed. Since significant differences were observed in group 4 compared to each single-drug treatment group, a two-way ANOVA (two-tailed) was performed to compare the compound A treatment group (groups 1 and 2) and the decitabine treatment group (group 3). The interaction effect between the groups (groups 3 and 4) was examined. 7) Results Compound A and decitabine showed antitumor effects against KG-1 tumors. Combination treatment of decitabine and compound A inhibited tumor growth significantly more strongly than single-agent treatment of each drug (Table 7, Figure 43). 8) Conclusion The combination of Compound A and decitabine was well tolerated and showed significant synergistic effects in the KG-1 tumor-bearing mouse model. These results support the implementation of clinical trials of the combination chemotherapy of Compound A and decitabine.
[0105] Example 41: Effect of combination of Compound A and cytarabine on human acute myeloid leukemia (AML) cell line KG-1 1) Test substance The compound A used was in the form of a bulk powder. Cytarabine (Kiloside [trademark] injection 60 mg) was purchased from Nippon Shinyaku Co., Ltd. and used. 2) Preparation of test substances Compound A was suspended in 1% hypromellose solution to prepare a 3 mg / mL solution of Compound A at 30 mg / kg. Cytarabine was diluted with saline to prepare a 5 mg / mL solution of Cytarabine at 50 mg / kg. 3) Cell KG-1 was obtained from the Human Science Research Resources Bank. The cells were cultured at 37°C and 5% CO2 in RPMI1640 medium supplemented with 10% inactivated (treated at 56°C for 30 minutes) fetal bovine serum. The collected cells were cultured at 2.5 × 10 8 The cells were suspended at 1000 cells / mL. 4)Animals Five-week-old female SCID mice (CB-17 / Icr-scid / scid Jcl, manufactured by CLEA Japan, Inc.) were used. The female SCID mice were bred in the same manner as in Example 36. The cell suspension was added at 5 × 10 7 The cells / body were subcutaneously transplanted into the right axilla of 6-week-old SCID mice, and the mice were divided into groups in the same manner as in Example 36 based on the tumor volume. 5) Administration and Measurement Administration began the day after group allocation (Day 2), and the final dose was administered on the day after the end of 14 days of medication (Day 16). Tumor size and body weight were measured and evaluated. Each group (N=6) was treated as follows. In order to match the combination group, the control group was administered the solvent of each drug, and the single drug administration group was administered the solvent of the combination drug, in the same manner as the combination group. (1) Control (solvent control) group: 1% hypromellose solution, saline (2) Compound A treatment group: Compound A 30 mg / kg (oral administration once a day for 14 consecutive days) (3) Cytarabine treatment group: Cytarabine 50 mg / kg (intraperitoneal administration on days 2, 3, 4, 5, 6, 9, 10, 11, 12, and 13) (4) Combination group: Compound A 30 mg / kg (oral administration once a day for 14 consecutive days) + cytarabine 50 mg / kg (intraperitoneal administration on days 2, 3, 4, 5, 6, 9, 10, 11, 12, and 13) Body weight and tumor diameter were measured over time using an electronic balance and electronic calipers. Tumor volume was calculated as (long diameter × [short diameter] 2 × 0.5). Antitumor activity was expressed as the ratio of relative tumor volume of each treatment group to the control group (T / C%). T / C% on day 16 was calculated for each group as the relative tumor volume on day 16 [(tumor volume on day 16 [Tumor volume on Day 1 of each group x 100] / mean phase trajectory on Day 16 of the control group Tumor volume [(tumor volume on Day 16 in the control group / tumor volume on Day 1 in the control group It was calculated using the formula: [volume] × 100 × 100. 6) Statistical analysis To examine the effect of the combination of compound A and cytarabine (group 4) on the relative tumor volume compared with compound A alone (group 2) and cytarabine alone (group 3), a Dunnett test (two-tailed) was performed. Since significant differences were observed in group 4 compared with each single-agent treatment group, a two-way ANOVA was performed. was carried out to examine the interaction effect between the compound A treatment group (groups 1 and 2) and the cytarabine treatment group (groups 3 and 4). 7) Results Compound A and cytarabine showed antitumor effects against KG-1 tumors. Combination treatment of cytarabine and compound A inhibited tumor growth significantly more strongly than single-agent treatment of each drug (Table 7, FIG. 44). 8) Conclusion The combination of compound A and cytarabine was well tolerated and showed significant synergistic effects in the KG-1 tumor-bearing mouse model. These results support the implementation of clinical trials of the combination chemotherapy of compound A and cytarabine.
[0106] [Table 7]
[0107] Example 42: Compounds in human diffuse large B-cell lymphoma cell line OCI-Ly7 Effect of combination therapy with A, bendamustine and rituximab 1) Test substance The bulk powder of compound A was used. Bendamustine was purchased from Tokyo Chemical Industry Co., Ltd. Stine hydrochloride hydrate was purchased from Genentech, Inc. and used. Rituximab (Rituxan [trademark] 100 mg / 10 mL) was purchased from Genentech, Inc. 2) Preparation of test substances Compound A was suspended in 1% hypromellose solution to prepare a 3 mg / mL (30 mg / kg administration solution) suspension of the test substance. Bendamustine was dissolved in saline to prepare a 1 mg / mL solution (10 mg / kg administration solution) just before use. Rituximab was diluted with saline to prepare a 1 mg / mL solution (10 mg / kg administration solution) just before use. 3) Cell OCI-Ly7 was obtained from DSMZ. The cells were cultured at 37°C and 5% CO2 in RPMI1640 medium supplemented with 10% inactivated fetal bovine serum (treated at 56°C for 30 minutes). The collected cells were cultured in serum-free RPMI1640 medium at a concentration of 1.5 × 10 8 The cells were suspended at 1000 cells / mL. 4)Animals Five-week-old female SCID mice (CB-17 / Icr-scid / scid Jcl, manufactured by CLEA Japan, Inc.) were used. The female SCID mice were bred in the same manner as in Example 36. The cell suspension was added at 3 × 10 7 The cells / body were subcutaneously transplanted into the right axilla of 6-week-old SCID mice, and the mice were divided into groups in the same manner as in Example 36 based on the tumor volume. 5) Administration and Measurement Administration began the day after grouping (Day 2), and Compound A was orally administered once a day for 14 consecutive days. Bendamustine was intraperitoneally administered a total of five times on Days 2, 3, 4, 5, and 6. Rituximab was intraperitoneally administered a total of two times on Days 2 and 9. In order to match the combination group, the control group was administered the solvent for each drug, and the single drug administration group was administered the solvent for the combination drug, in the same manner as the combination group. All animals were orally administered daily for 14 days, and intraperitoneally administered on Days 2, 3, 4, 5, 6, and 9. Each group (N=6) was treated as follows. (1) Control (solvent control) group: 1% hypromellose solution, saline (2) Compound A (30 mg / kg) treatment group: Compound A 30 mg / kg (administered orally once a day for 14 consecutive days) (3) Bendamustine (10 mg / kg) + Rituximab (10 mg / kg) treatment group: Bendamustine 10 mg / kg (intraperitoneal administration on days 2, 3, 4, 5, and 6) + Rituximab 10 mg / kg (intraperitoneal administration on days 2 and 9) (4) Triple-drug combination group: Compound A 30 mg / kg (administered orally once a day for 14 consecutive days) + Bendamustine 10mg / kg (intraperitoneal administration on Days 2, 3, 4, 5, and 6) + Rituximab 10mg / kg (intraperitoneal administration on Days 2 and 9) Measurements were performed in the same manner as in Example 36, and tumor growth delay was calculated and statistically analyzed. 6) Results The time to 800% relative tumor volume, which was the evaluation endpoint, was 9.9 days (median time) in the control group. The tumor growth delay rate (%) in the compound A (30 mg / kg) treatment group was 83.8%. The tumor growth delay rate (%) in the bendamustine (10 mg / kg) + rituximab (10 mg / kg) treatment group was 144.4%. Compound A 30 mg / kg and bendamustine 10 mg / kg plus rituximab 10 mg / kg were shown to be effective. The triple therapy consisted of compound A 30mg / kg + bendamustine 10mg / kg + rituximab The tumor growth delay rate (%) in the 10 mg / kg simab group was >829.3%. When compound A was administered in combination with bendamustine and rituximab, there was no significant interaction with the triple combination effect. The triple-drug combination effect was significantly synergistic, and the triple-drug combination treatment resulted in complete tumor regression (Table 8, Figure 45). 7) Conclusion Compound A 30mg / kg monotherapy, bendamustine 10mg / kg + rituximab 10mg / kg, and combination treatment with Compound A 30mg / kg and Bendamustine 10mg / kg The triple combination of 10 mg / kg of rituximab and 10 mg / kg of rituximab demonstrated significant antitumor activity in the OCI-Ly7 tumor-bearing mouse model. The results showed a significant synergistic effect.
[0108] [Table 8]
[0109] Example 43: Effect of triple combination therapy of Compound A, decitabine, and venetoclax in human acute myeloid leukemia (AML) cell line KG-1 1) Test substance The bulk powder of compound A was used. Venetoclax was purchased from Elsie Laboratories. Decitabine (5-aza-2′-deoxycytidine) was purchased from Tokyo Chemical Industry Co., Ltd. 2) Preparation of test substances Compound A and venetoclax were suspended in 1% hypromellose solution to prepare a 50 mg / kg dose of Compound A at 5 mg / mL. Decitabine was diluted with saline to 0.1 mg A 1 mg / kg decitabine solution was prepared in 1 mL of 1000 mM NaCl. 3) Cell KG-1 was obtained from the Human Science Research Resources Bank. The cells were cultured at 37°C and 5% CO2 in RPMI1640 medium supplemented with 10% inactivated (treated at 56°C for 30 minutes) fetal bovine serum. The collected cells were cultured at 2.5 × 10 8 The cells were suspended at 1000 cells / mL. 4)Animals Five-week-old female SCID mice (CB-17 / Icr-scid / scid Jcl, manufactured by CLEA Japan, Inc.) were used. The female SCID mice were bred in the same manner as in Example 36. The cell culture medium was added at 5 × 10 7 The cells / body were subcutaneously transplanted into the right axilla of 6-week-old SCID mice, and the mice were divided into groups in the same manner as in Example 36 based on the tumor volume. 5) Administration and Measurement Administration began the day after grouping (Day 2), and tumor size and body weight were measured and evaluated the day after the end of 14 days of medication (Day 16). Each group (N=6) was treated as follows. In order to match the combination group, the control group was administered the solvent for each drug, and the single drug administration group was administered the solvent for the combination drug, in the same way as the combination group. (1) Control (solvent control) group: 1% hypromellose solution, saline (2) Compound A treatment group: Compound A 50 mg / kg (administered orally once daily for 14 days) (3) Venetoclax + decitabine treatment group: Venetoclax 50 mg / kg (administered orally once daily for 14 days) + decitabine 1 mg / kg (administered intraperitoneally on days 2, 5, 9, and 12) (4) Triple-drug combination group: Compound A 50 mg / kg (administered orally once a day for 14 consecutive days) + Netoclax 50mg / kg (oral administration once daily for 14 days) + decitabine 1mg / kg (intraperitoneal administration on days 2, 5, 9, and 12) Body weight and tumor diameter were measured over time using an electronic caliper (Mitutoyo Corporation). Tumor volume was calculated as (long diameter × [short diameter] 2 Antitumor activity was expressed as the ratio of relative tumor volume of each treatment group to the control group (T / C%). T / C% on day 16 was calculated for each group by dividing the relative tumor volume on day 16 [(tumor volume on day 16 Tumor volume / tumor volume on Day 1 of each group × 100 / average tumor volume on Day 16 of the control group Mean relative tumor volume [(tumor volume on Day 16 in the control group / tumor volume on Day 1 in the control group The tumor volume was calculated using the formula: [tumor volume] × 100 × 100. 6) Statistical analysis A Dunnett's test (two-tailed) was performed to examine the effect of the triple combination of Compound A, venetracx, and decitabine (Group 4) on relative tumor volume compared to Compound A alone (Group 2) and venetoclax + decitabine (Group 3). Because significant differences were observed in Group 4 compared to Groups 2 and 3, a two-way ANOVA (two-tailed) was performed to compare the relative tumor volume between the control group and the Compound A treatment group. (groups 1 and 2) and the venetoclax + decitabine and triple combination groups (groups 3 and 4). The interaction effect was evaluated. 7) Results Compound A, venetoclax, and decitabine demonstrated antitumor activity against KG-1 tumors. The triple combination treatment of venetoclax, decitabine, and compound A was more effective than compound A alone and venetoclax. The inhibition of tumor growth was significantly stronger than that achieved by administration of netoclax + decitabine (Table 9, Figure 46). 8) Conclusion The triple combination therapy of Compound A, venetoclax, and decitabine improved the survival of KG-1 tumor-bearing mice "The results support the initiation of clinical trials of compound A in combination with venetoclax and decitabine in a triple chemotherapy setting," said Dr.
[0110] [Table 9]
Claims
1. An antitumor composition comprising the following compound (B) or a salt thereof for use in combination with the following antitumor agent (A). (A) at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, folate antimetabolites, Bcl-2 inhibitors, and tyrosine kinase inhibitors; (B) The following formula (1): 【Chemistry 1】 (In the formula, R 1 represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group which may be substituted by one or more halogen atoms; R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, m represents an integer from 1 to 3, provided that when m represents 2 or 3, R 1 are the same or different) or a salt thereof
2. An antitumor composition comprising the following compound (B) or a salt thereof, which is used to be administered to a person who will be administered or has been administered the following antitumor agent (A). (A) at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, folate antimetabolites, Bcl-2 inhibitors, and tyrosine kinase inhibitors; (B) The following formula (1): 【Chemistry 2】 (In the formula, R 1 represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group which may be substituted by one or more halogen atoms; R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, m represents an integer from 1 to 3, provided that when m represents 2 or 3, R 1 are the same or different) or a salt thereof
3. The following antitumor agent (A): The following compound (B) or a salt thereof:
13. An antitumor composition comprising: (A) Alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine metabolic antagonists at least one antitumor agent selected from the group consisting of anticancer agents, purine antimetabolites, folate antimetabolites, Bcl-2 inhibitors, and tyrosine kinase inhibitors; (B) The following formula (1): 【Chemistry 3】 (In the formula, R 1 represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group which may be substituted by one or more halogen atoms; R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, m represents an integer from 1 to 3, provided that when m represents 2 or 3, R 1 are the same or different) or a salt thereof
4. The compound (B) or a salt thereof is N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide, N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide, N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, 2-fluoro-N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, 2,3,4-trifluoro-N-{6-[2-fluoro-4-(methylamino)phenoxy]pyridin-3-yl}benzamide, N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide, N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide, N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, 2-fluoro-N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide], N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide, N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}-4-phenoxybenzamide, N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}biphenyl-4-carboxamide, 2-fluoro-N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, 2,3,4-trifluoro-N-{6-[2-methoxy-4-(methylamino)phenoxy]pyridin-3-yl}benzamide, 2,3,4-trifluoro-N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}benzamide, N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, 2-fluoro-N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, and 2,3,4-trifluoro-N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}benzamide At least one compound selected from the group consisting of or a salt thereof, The composition according to any one of claims 1 to 3.
5. The following antitumor agent (A): An antitumor composition comprising the following compound (B) or a salt thereof: A kit comprising: (A) at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, folate antimetabolites, Bcl-2 inhibitors, and tyrosine kinase inhibitors; (B) The following formula (1): 【Chemistry 4】 (In the formula, R 1 represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group which may be substituted by one or more halogen atoms, R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, m represents an integer from 1 to 3, provided that when m represents 2 or 3, R 1 are the same or different) or a salt thereof
6. A method for preventing or treating a tumor, comprising administering to a subject an antitumor agent represented by the following formula (A) and a compound represented by the following formula (B) or a salt thereof. (A) at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, folate antimetabolites, Bcl-2 inhibitors, and tyrosine kinase inhibitors; (B) The following formula (1): 【Chemistry 5】 (In the formula, R 1 represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group which may be substituted by one or more halogen atoms; R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, m represents an integer from 1 to 3, provided that when m represents 2 or 3, R 1 are the same or different) or a salt thereof
7. A compound represented by the following (B) or a salt thereof for use in combination with an antitumor agent represented by the following (A) in the prevention or treatment of tumors. (A) at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, folate antimetabolites, Bcl-2 inhibitors, and tyrosine kinase inhibitors; (B) The following formula (1): 【Chemistry 6】 (In the formula, R 1 represents a halogen atom, an aryl group, an aryloxy group, or a lower alkyl group which may be substituted by one or more halogen atoms; R 2 represents a hydrogen atom, a halogen atom, a lower alkyl group, or a lower alkoxy group, m represents an integer from 1 to 3, provided that when m represents 2 or 3, R 1 are the same or different) or a salt thereof
Citation Information
Patent Citations
4- (methylaminophenoxy) pyrdin- 3 - YL - benzamide derivatives for treating cancer
WO2012046825A1
